TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24736301

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 907
Study: 23520213

Group type: EXPERIMENTAL
Intervention: MRP Support app
Number of subjects: 58

Group type: COMPARATOR
Intervention: Static app based on MRP information
Number of subjects: 58
Study: 21568691

Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 185

Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 185
Study: 18692826

Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery ligation and myomectomy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Laparoscopic myomectomy only
Number of subjects: 152
Study: 16563917

Group type: EXPERIMENTAL
Intervention: Tolvaptan (10 mg/day, increased to 60 mg/day as needed)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluid restriction (1,200 ml/day) plus placebo
Number of subjects: 28
Study: 12836579

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive and coping measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment mediation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive change and enhanced coping
Number of subjects: 0
Study: 11308035

Group type: EXPERIMENTAL
Intervention: Lifetime major depression
Number of subjects: 136

Group type: COMPARATOR
Intervention: No lifetime major depression
Number of subjects: 136
Study: 9052581

Group type: EXPERIMENTAL
Intervention: Sublingual administration of micronized 17 beta-estradiol (1 mg, 0.5 mg, 0.25 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral administration of micronized 17 beta-estradiol (1 mg, 0.5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sublingual administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral administration
Number of subjects: 6
Study: 8336809

Group type: EXPERIMENTAL
Intervention: Intra-arterial mannitol infusion (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No intra-arterial mannitol infusion (group B)
Number of subjects: 39
Study: 3110799

Group type: EXPERIMENTAL
Intervention: T3, 100 micrograms orally
Number of subjects: 34

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 34
Study: 30320574

Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Music listening (ML)
Number of subjects: 53
Study: 27304433

Group type: EXPERIMENTAL
Intervention: 1.5 mg basimglurant MR
Number of subjects: 333

Group type: COMPARATOR
Intervention: 0.5 mg basimglurant MR
Number of subjects: 333
Study: 24856571

Group type: EXPERIMENTAL
Intervention: Active cranial electrotherapy stimulation (CES)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sham cranial electrotherapy stimulation (CES)
Number of subjects: 115
Study: 23547081

Group type: COMPARATOR
Intervention: Gemcitabine (1,000 mg/m² on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 834

Group type: COMPARATOR
Intervention: S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Gemcitabine plus S-1 (gemcitabine 1,000 mg/m² on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle)
Number of subjects: 834

Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 834

Group type: COMPARATOR
Intervention: Gemcitabine plus S-1
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 834
Study: 16002778

Group type: EXPERIMENTAL
Intervention: nPAP >10 cmH(2)O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nPAP
Number of subjects: 10
Study: 12601627

Group type: EXPERIMENTAL
Intervention: Daily multivitamin therapy including 1 mg of folic acid for 4 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Supplementation with 1 mg vitamin B(12) for an additional 4 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High-dose vitamin therapy (folic acid and vitamin B(12))
Number of subjects: 81

Group type: COMPARATOR
Intervention: MTHFR genotype influence
Number of subjects: 81
Study: 10921058

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual palpation
Number of subjects: 60
Study: 7832258

Group type: EXPERIMENTAL
Intervention: Cloth diapers with front closure and all-in-one design
Number of subjects: 1722

Group type: COMPARATOR
Intervention: Paper diapers containing absorbent gel material
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: Cloth diapers (second period)
Number of subjects: 1722
Study: 2141299

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine and naproxen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen alone
Number of subjects: 40
Study: 90218

Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg three times a day for 3-12 months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 96 mg/day for 7 days
Number of subjects: 47
Study: 29096938

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156
Study: 27858585

Group type: EXPERIMENTAL
Intervention: Health news from government officials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health news from physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High severity condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low severity condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mention of self-efficacy method present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mention of self-efficacy method absent
Number of subjects: 0
Study: 24792763

Group type: EXPERIMENTAL
Intervention: Subjective outcome evaluation measures (process, program, effectiveness) at Wave 3
Number of subjects: 2784

Group type: EXPERIMENTAL
Intervention: Subjective outcome evaluation measures
Number of subjects: 2784

Group type: EXPERIMENTAL
Intervention: CPYDS scores at Wave 4
Number of subjects: 2784
Study: 22743678

Group type: EXPERIMENTAL
Intervention: Tralokinumab (150, 300 or 600 mg)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 20824270

Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg QID)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 19194355

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (including circumferential dissection of both the celiac axis and the superior mesenteric artery and resection of para-aortic nodes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 0
Study: 16009860

Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 3778

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3778

Group type: EXPERIMENTAL
Intervention: Parenteral anticoagulant agent or warfarin
Number of subjects: 3778

Group type: EXPERIMENTAL
Intervention: Unfractionated or low‐molecular‐weight heparin
Number of subjects: 3778

Group type: EXPERIMENTAL
Intervention: Bridge therapy (injectable anticoagulant agent plus warfarin)
Number of subjects: 3778

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 3778
Study: 12450599

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 10101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study: 10709504

Group type: EXPERIMENTAL
Intervention: Treatment-resistant periodontitis patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with severe marginal periodontitis who had responded to treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control individuals without marginal periodontitis
Number of subjects: 0
Study: 7747700

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 395

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 395
Study: 2182977

Group type: EXPERIMENTAL
Intervention: Social support during pregnancy and postnatal period
Number of subjects: 459

Group type: COMPARATOR
Intervention: Delay of more than half an hour between birth and first suckling
Number of subjects: 459

Group type: COMPARATOR
Intervention: Pethidine during labour
Number of subjects: 459

Group type: COMPARATOR
Intervention: Complementary bottle feeds
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 459
Study: 7208079

Group type: EXPERIMENTAL
Intervention: Non-painful and painful electrical stimuli
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Painful electrical stimuli
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical stimuli of varying intensities
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Skin resistance reaction and withdrawal reflex amplitude
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subjective estimation of pain
Number of subjects: 15
Study: 30955909

Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation (SM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 14
Study: 27796775

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (DPP)
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (HELP PD)
Number of subjects: 3535

Group type: COMPARATOR
Intervention: Enhanced usual care (HELP PD)
Number of subjects: 3535
Study: 25457871

Group type: EXPERIMENTAL
Intervention: 3D titanium miniplate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard titanium miniplate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study: 24207163

Group type: EXPERIMENTAL
Intervention: Primary Care Triple P (PCTP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Care as usual (UC)
Number of subjects: 81
Study: 21315841

Group type: EXPERIMENTAL
Intervention: CRT responders (n = 32)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CRT nonresponders (n = 19)
Number of subjects: 54
Study: 19625315

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 199
Study: 17458427

Group type: EXPERIMENTAL
Intervention: Asthma controller medication adherence
Number of subjects: 200

Group type: COMPARATOR
Intervention: Physician instruction to use controller medication intermittently
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Desire for control over treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Perception of information adequacy
Number of subjects: 200
Study: 15063247

Group type: EXPERIMENTAL
Intervention: Skeletonized internal thoracic artery graft
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pedicled internal thoracic artery graft
Number of subjects: 19
Study: 11411906

Group type: EXPERIMENTAL
Intervention: 0.1% isotretinoin cream with chemical sunscreens
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4% benzoyl peroxide cream
Number of subjects: 0
Study: 9580420

Group type: EXPERIMENTAL
Intervention: Participation in a pharmacological hypolipidaemic trial (12 weeks)
Number of subjects: 106
Study: 7978429

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA) (T1‐5 block)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (standardized fentanyl-nitrous oxide anesthesia without TEA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TEA group
Number of subjects: 20
Study: 2657675

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 25 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 1211587

Group type: EXPERIMENTAL
Intervention: Topical analgesia using lignocaine applied to the pyriform fossae for superior laryngeal nerve block and topical analgesia of larynx and trachea.
Number of subjects: 0
Study: 31760855

Group type: EXPERIMENTAL
Intervention: Telemonitoring and telecoaching (TELE) for six months
Number of subjects: 122

Group type: COMPARATOR
Intervention: Traditional six-month follow-up programme with monthly calls (CON)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Telemonitoring and telecoaching (TELE)
Number of subjects: 122
Study: 29673620

Group type: EXPERIMENTAL
Intervention: Hydromorphone 2mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydromorphone 4mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28177706

Group type: EXPERIMENTAL
Intervention: BCAA (0.087 g/kg body mass)
Number of subjects: 16
Study: 25117999

Group type: EXPERIMENTAL
Intervention: Tuna fish oil (high in long-chain omega-3 fatty acids)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Sunola oil (low in omega-3 fatty acids)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Plasma omega-3 fatty acid levels
Number of subjects: 616
Study: 23261884

Group type: EXPERIMENTAL
Intervention: Instructions to remove clothing
Number of subjects: 99

Group type: COMPARATOR
Intervention: No instructions about clothing removal
Number of subjects: 99
Study: 21618205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Severe fibrosis (HRCT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: No or moderate fibrosis (HRCT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Severe fibrosis with disease duration 0-2 years
Number of subjects: 79
Study: 18643896

Group type: EXPERIMENTAL
Intervention: 15 Hz rapid-rate lumbosacral magnetic stimulation (rLSMS) for 15 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 Hz rapid-rate lumbosacral magnetic stimulation (rLSMS) for 15 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham rapid-rate lumbosacral magnetic stimulation (rLSMS) for 15 min
Number of subjects: 8
Study: 16540962

Group type: EXPERIMENTAL
Intervention: Povidone-iodine group (20 mL of a 10% povidone-iodine aqueous solution rinsing)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Saline group (60 mL of saline solution rinsing)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (standard regimen without instillation, aspiration of oropharyngeal secretions)
Number of subjects: 98
Study: 12684129

Group type: EXPERIMENTAL
Intervention: Selenium and vitamin E supplementation
Number of subjects: 32400

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32400
Study: 10856105

Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (HDI) for 1 year
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Low-dose interferon alfa-2b (LDI) for 2 years
Number of subjects: 642

Group type: COMPARATOR
Intervention: Observation (Obs)
Number of subjects: 642
Study: 8647566

Group type: EXPERIMENTAL
Intervention: Crataegus (Hawthorn)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 1345870

Group type: EXPERIMENTAL
Intervention: Routine ultrasonography (screened group)
Number of subjects: 2011
Study: 6142252

Group type: EXPERIMENTAL
Intervention: Towne strain cytomegalovirus (CMV) vaccine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 31125354

Group type: EXPERIMENTAL
Intervention: RESPOND (telephone-based patient-centred falls prevention program)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 430
Study: 29329499

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 37
Study: 27704167

Group type: COMPARATOR
Intervention: Single-hormone artificial pancreas
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 17
Study: 24853314

Group type: COMPARATOR
Intervention: Wound infiltration (WI) with 1 mg·kg(‐1) 0.25% bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided rectus sheath block (USGRSB) with 0.5 mg·kg(‐1) 0.25% bupivacaine per side
Number of subjects: 40
Study: 22832531

Group type: EXPERIMENTAL
Intervention: Fortified balanced salt solution (BSS Plus)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ringer lactate
Number of subjects: 70
Study: 20176428

Group type: EXPERIMENTAL
Intervention: Story-based safety messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concrete (non-anecdotal) safety messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional abstract safety messages
Number of subjects: 0
Study: 17907207

Group type: EXPERIMENTAL
Intervention: ESCAPE-knee pain (Indiv-rehab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ESCAPE-knee pain (Grp-rehab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indiv-rehab vs Grp-rehab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ESCAPE-knee pain (Indiv-rehab and Grp-rehab)
Number of subjects: 0
Study: 16901887

Group type: EXPERIMENTAL
Intervention: Male condom-focused HIV prevention intervention
Number of subjects: 201
Study: 12496325

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 729
Study: 9806648

Group type: EXPERIMENTAL
Intervention: High dose chemoradiotherapy with 5-fluorouracil (5-FU) and mitomycin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High dose chemoradiotherapy with 5-FU and mitomycin
Number of subjects: 46
Study: 7659873

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate‐trometamol‐phosphate mixture (250 ml with buffering capacity 500 mmol/l)
Number of subjects: 502

Group type: COMPARATOR
Intervention: 0.9% saline (250 ml)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Buffer therapy (sodium bicarbonate)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 502
Study: 2503620

Group type: EXPERIMENTAL
Intervention: Immediate arteriographic evaluation (AG)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Delayed arteriographic evaluation (AG)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Arteriographic evaluation (AG)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Soft clinical signs
Number of subjects: 135
Study: 1046183

Group type: EXPERIMENTAL
Intervention: Behavior modification training in body positioning
Number of subjects: 10

Group type: COMPARATOR
Intervention: Customary body positioning nursing care
Number of subjects: 10
Study: 6118631

Group type: EXPERIMENTAL
Intervention: 2.5 mg ergocalciferol (oral and intramuscular administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 mg ergocalciferol (oral administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 mg ergocalciferol (once a year regimen)
Number of subjects: 0
Study: 31082847

Group type: EXPERIMENTAL
Intervention: Dorsoulnar incision
Number of subjects: 46

Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dorsoulnar incision with immobilization
Number of subjects: 46

Group type: COMPARATOR
Intervention: Midline incision with early mobilization
Number of subjects: 46
Study: 31122178

Group type: EXPERIMENTAL
Intervention: Translational-rotational shifts in 6 degrees of freedom (X, Y, Z, α, β, γ)
Number of subjects: 20
Study: 27629405

Group type: EXPERIMENTAL
Intervention: Personalised Hip Therapy (PHT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (arthroscopic surgery)
Number of subjects: 42
Study: 24829210

Group type: EXPERIMENTAL
Intervention: Deep-TMS treatment (20 daily sessions at 20Hz, 120% MT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 22527609

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 102

Group type: COMPARATOR
Intervention: Problem-solving
Number of subjects: 102

Group type: COMPARATOR
Intervention: Rumination
Number of subjects: 102

Group type: COMPARATOR
Intervention: Distraction (Study 1)
Number of subjects: 102
Study: 19640833

Group type: EXPERIMENTAL
Intervention: Condition 1: 'Guía Para Dejar de Fumar', a static National Cancer Institute evidence‐based stop smoking guide
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Condition 2: Condition 1 plus E‐mail reminders to return to the site
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Condition 3: Condition 2 plus mood management lessons
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Condition 4: Condition 3 plus a 'virtual group' (an asynchronous bulletin board)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (missing data assumed to be smoking)
Number of subjects: 1000
Study: 17642239

Group type: EXPERIMENTAL
Intervention: Rituximab with concomitant MTX therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16313283

Group type: EXPERIMENTAL
Intervention: Tramadol 37.5 mg/paracetamol 325 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Codeine 30 mg/paracetamol 500 mg
Number of subjects: 24
Study: 12407042

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 82
Study: 9521260

Group type: EXPERIMENTAL
Intervention: glatiramer acetate (Copaxone)
Number of subjects: 251

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 251
Study: 7855200

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2563308

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 56648

Group type: EXPERIMENTAL
Intervention: Hydrocortisone stimulation test
Number of subjects: 10
Study: 31794027

Group type: EXPERIMENTAL
Intervention: mhGAP-based training (6 weeks, weekly sessions including lectures, discussions, role plays, and support sessions)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: mhGAP-based training (Group 1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (Group 2, received training after Group 1)
Number of subjects: 112
Study: 31187764

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 90